Relay To Take On AstraZeneca With RLY-2608 In PI3Kα-Mutated Breast Cancer
The firm is planning a head-to-head trial against AstraZeneca’s Truqap after RLY-2608 showed better safety and efficacy in a Phase I trial, including a four-month PFS benefit.

The firm is planning a head-to-head trial against AstraZeneca’s Truqap after RLY-2608 showed better safety and efficacy in a Phase I trial, including a four-month PFS benefit.